Chronic prurigo in an adolescent patient successfully controlled with dupilumab.

Chronic prurigo, formerly termed prurigo nodularis, is a chronic skin condition characterized by intensely itchy nodules and papules. It primarily affects adults, particularly middle-aged women. The aetiology of chronic prurigo is unclear, but it can be associated with primary skin dermatoses and systemic conditions. Minimal data on chronic prurigo in children are available in the literature. While systemic therapies for chronic prurigo have significant side effects, targeted biologic and small--molecule inhibitors offer a promising treatment option with a good benefit-risk ratio. We report one of the first cases of an adolescent with chronic prurigo that was successfully controlled with dupilumab. Dupilumab treatment resulted in a fast, significant and sustainable improvement in the signs and symptoms of chronic prurigo, with favourable safety and tolerability profiles, highlighting its potential for recalcitrant cases and long-term remission.